Supplementary Data — Sargramostim for COVID-19: real-time meta analysis of 4 studies

@CovidAnalysis, November 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ SARPAC Bosteels (RCT) -2% 1.02 [0.15-6.93] death 2/40 2/41 Improvement, RR [CI] Treatment Control SARPAC Bosteels (RCT) -20% 1.20 [0.44-3.25] ventilation 7/40 6/41 SARPAC Bosteels (RCT) -10% 1.10 [0.60-2.01] misc. 40 (n) 41 (n) SARPAC Bosteels (RCT) 33% 0.67 [0.05-8.60] misc. 40 (n) 41 (n) SARPAC Bosteels (RCT) 20% 0.80 [0.23-2.81] misc. 40 (n) 41 (n) SARPAC Bosteels (RCT) 43% 0.57 [0.28-1.18] oxygen 40 (n) 41 (n) iLeukPulm Paine (RCT) 23% 0.77 [0.31-1.92] death 78 (n) 44 (n) iLeukPulm Paine (RCT) 15% 0.85 [0.30-2.39] death 78 (n) 44 (n) iLeukPulm Paine (RCT) 27% 0.73 [0.29-1.81] ventilation 9/78 7/44 iLeukPulm Paine (RCT) 56% 0.44 [0.21-0.90] oxygen 10/63 12/33 iLeukPulm Paine (RCT) -3% 1.03 [0.79-1.33] hosp. time 78 (n) 44 (n) Shimasaki (DB RCT) -305% 4.05 [0.20-80.9] ventilation 2/44 0/23 Shimasaki (DB RCT) -57% 1.57 [0.17-14.2] no disch. 3/44 1/23 Shimasaki (DB RCT) -12% 1.12 [0.98-1.29] no improv. 47 (n) 23 (n) Joshi (DB RCT) -30% 1.30 [0.69-2.45] progression 21/301 16/299 Joshi (DB RCT) 27% 0.73 [0.58-0.91] viral load 50 (n) 51 (n) Sargramostim COVID-19 outcomes c19early.org November 2025 Favors sargramostim Favors control
Fig. S1. All outcomes.